Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Authors
Keywords
antibody drug conjugate, biotherapeutics, cancer, pharmacokinetics, preclinical
Journal
PHARMACEUTICAL RESEARCH
Volume 32, Issue 11, Pages 3470-3479
Publisher
Springer Nature
Online
2014-12-02
DOI
10.1007/s11095-014-1584-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
- (2014) Brendan Bender et al. AAPS Journal
- Measurement of in Vivo Drug Load Distribution of Cysteine-Linked Antibody–Drug Conjugates Using Microscale Liquid Chromatography Mass Spectrometry
- (2014) Shawna Mae Hengel et al. ANALYTICAL CHEMISTRY
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
- (2014) Dan Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Analytical and bioanalytical technologies for characterizing antibody–drug conjugates
- (2013) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Advancing Antibody Drug Conjugation
- (2013) Nicole M. Okeley et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Target-mediated drug disposition model and its approximations for antibody–drug conjugates
- (2013) Leonid Gibiansky et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
- (2013) Nahor Haddish-Berhane et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Antibody-drug conjugates
- (2013) Alain Beck et al. mAbs
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
- (2013) Kirsten Achilles Poon et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Characterization of the drug-to-antibody ratio distribution for antibody–drug conjugates in plasma/serum
- (2013) Keyang Xu et al. Bioanalysis
- Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper
- (2013) Boris Gorovits et al. Bioanalysis
- Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics
- (2013) Surinder Kaur et al. Bioanalysis
- ADME of Antibody–Maytansinoid Conjugates
- (2012) Hans K. Erickson et al. AAPS Journal
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Drug-conjugated antibodies for the treatment of cancer
- (2012) John M. Lambert BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antibody-Drug Conjugates for the Treatment of Cancer
- (2012) John A. Flygare et al. Chemical Biology & Drug Design
- Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer
- (2012) V L Chudasama et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
- (2012) Ben-Quan Shen et al. CURRENT DRUG METABOLISM
- Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
- (2012) Rong Deng et al. Expert Opinion on Drug Metabolism & Toxicology
- Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
- (2012) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Pharmacokinetic Considerations for Antibody Drug Conjugates
- (2012) Kedan Lin et al. PHARMACEUTICAL RESEARCH
- Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry
- (2011) Keyang Xu et al. ANALYTICAL BIOCHEMISTRY
- Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
- (2011) Xiuxia Sun et al. BIOCONJUGATE CHEMISTRY
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2010) J. R. Junutula et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Effect of Immune Complex Formation on the Distribution of a Novel Antibody to the Ovarian Tumor Antigen CA125
- (2010) C. V. Pastuskovas et al. DRUG METABOLISM AND DISPOSITION
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
- Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
- (2009) R. A. Herbertson et al. CLINICAL CANCER RESEARCH
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started